A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 133 participants.

Also called NCT04671771

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 133 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04671771
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04671771. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-03 (actual); primary completion 2030-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
Condition
End Stage Renal Disease (ESRD)
Condition
Kidney Failure
Condition
Chronic Renal Disease
Condition
Hemodialysis
Intervention (Device)
InnAVasc Arteriovenous Graft (IG) surgical implant
Lead sponsor
W.L.Gore & Associates (class: industry)

Record details

Record id
cardio:ct-nct04671771
Content hash
8487ed2866c72b0cd4cac91f0263f08965f9ba98a8c6b605bf8223a585bec035